Bain Capital Life Sciences Investors’s Nuvalent NUVL Stock Holding History

Bain Capital Life Sciences Investors’s Portfolio NUVL Stock Details NUVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,447,267	Closed	-$110M	–	24
2025 Q2	$110M	Hold	1,447,267	–	–	13.82%	3
2025 Q1	$103M	Hold	1,447,267	–	–	15.19%	2
2024 Q4	$113M	Sell	1,447,267 -1,250,000	-46%	-$117M	13.33%	2
2024 Q3	$276M	Hold	2,697,267	–	–	28.71%	1
2024 Q2	$205M	Hold	2,697,267	–	–	22.46%	1
2024 Q1	$203M	Sell	2,697,267 -880,000	-25%	-$70M	16.28%	2
2023 Q4	$263M	Hold	3,577,267	–	–	25.23%	1
2023 Q3	$164M	Hold	3,577,267	–	–	18.39%	1
2023 Q2	$151M	Hold	3,577,267	–	–	15.54%	1
2023 Q1	$93.3M	Hold	3,577,267	–	–	11.66%	2
2022 Q4	$107M	Buy	3,577,267 +149,253	+4%	+$4.16M	11.9%	2
2022 Q3	$66.6M	Hold	3,428,014	–	–	7.95%	2
2022 Q2	$46.5M	Hold	3,428,014	–	–	5.45%	6
2022 Q1	$47.6M	Hold	3,428,014	–	–	4.62%	6
2021 Q4	$65.3M	Hold	3,428,014	–	–	5.18%	6
2021 Q3	$77.3M	Buy	+3,428,014	New	+$99.5M	4.8%	7

Other funds holding NUVL

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bain Capital Life Sciences Investors's NUVL Position: Q3 2025 in Review

Bain Capital Life Sciences Investors sold out of Nuvalent (NUVL) in Q3 2025, closing a stake of 1,447,267 shares — an estimated $110M sold.

Bain Capital Life Sciences Investors first reported a position in NUVL in Q3 2021 and held it in 16 quarters. The position peaked at $276M in Q3 2024. 196 funds tracked by Wall St. Rank hold NUVL as of Q3 2025.

Bain Capital Life Sciences Investors reported no remaining Nuvalent position as of Q3 2025 after selling out during the quarter.
Bain Capital Life Sciences Investors sold 1,447,267 Nuvalent shares in Q3 2025, an estimated $110M.
Bain Capital Life Sciences Investors first reported a position in Nuvalent in Q3 2021 and held it in 16 quarters.
Bain Capital Life Sciences Investors's Nuvalent position peaked at $276M in Q3 2024.
196 funds tracked by Wall St. Rank held Nuvalent as of Q3 2025.

Based on Bain Capital Life Sciences Investors's 13F filing for Q3 2025, filed 14 Nov 2025.